Different Doses of Dexmedetomidine Combined With Esketamine in Women Undergoing Cesarean Delivery
Launched by PEKING UNIVERSITY FIRST HOSPITAL · Sep 23, 2024
Trial Information
Current as of July 30, 2025
Completed
Keywords
ClinConnect Summary
Esketamine is a commonly used anesthetic and analgesic drug during the perioperative period. Recent studies found that low-dose esketamine has rapid onset antidepressant effects and reduces postpartum depression when administered during cesarean delivery. However, even low-dose esketamine produces transient neuropsychiatric symptoms.
Dexmedetomidine is a high selective alpha2-adrenoceptor agonist and has both sedative and analgesic effects. When used in combination with esketamine, dexmedetomidine reduces esketamine related neuropsychiatric adverse reactions in patients undergoing general ...
Gender
FEMALE
Eligibility criteria
- Inclusion criteria:
- • Pregnant women aged ≥18 years.
- • Scheduled for elective or emergency cesarean delivery under neuraxial anesthesia.
- Exclusion criteria:
- • A previous history of schizophrenia;
- • Severe complications of pregnancy, such as pre-eclampsia, placenta accreta spectrum, or HELLP (intravascular haemolysis, elevated liver enzymes, and low platelet count) syndrome; or American Society of Anesthesiologists classification III or higher;
- • Any contraindications to ketamine or esketamine, such as refractory hypertension, severe cardiovascular disease, or hyperthyroidism;
- • Any contraindications to dexmedetomidine, such as sick sinus syndrome, severe sinus bradycardia (\<50 beats per minute), or second-degree or above atrioventricular block without pacemaker;
- • Other conditions that are considered unsuitable for study participation.
About Peking University First Hospital
Peking University First Hospital is a leading medical institution in China, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its extensive expertise in various medical fields to conduct rigorous studies aimed at improving patient outcomes and contributing to global medical knowledge. With a multidisciplinary team of skilled researchers and clinicians, Peking University First Hospital is dedicated to the ethical conduct of clinical research, ensuring the highest standards of safety and efficacy in its trials. The institution plays a vital role in translating scientific discoveries into effective treatments, thereby enhancing the quality of care for patients both locally and worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Dong-Xin Wang, M.D., PhD.
Principal Investigator
Peking University First Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported